ReviewClinical and experimental immunology2011
Monitoring of human papillomavirus vaccination.
Review in Clinical and experimental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- The structural and organizational aspects of human papillomavirus vaccine affecting immunization coverage in Europe: a systematic review.BMC public health · 2025Pooled it
- Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.The Cochrane database of systematic reviews · 2018Pooled it
- Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Human gene therapy · 2014Trial
- Human papillomavirus vaccine: Success and challenges.Journal of biosciences · 2025Review
- Article
- Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers.Medical journal of the Islamic Republic of Iran · 2021Review
- The HPV16 Genome Is Stable in Women Who Progress toCancer research · 2019Article
- Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination.PloS one · 2016Article
- Molecular diagnosis and phylogenetic analysis of human papillomavirus type-16 from suspected patients in Pakistan.Infectious agents and cancer · 2016Article
- HPV vaccine: Current status and future directions.Medical journal, Armed Forces India · 2015Review
- Immune therapy for human papillomaviruses-related cancers.World journal of clinical oncology · 2014Review
- Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination.American journal of epidemiology · 2013Article
- Broadening the translational immunology landscape.Clinical and experimental immunology · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.